共查询到20条相似文献,搜索用时 15 毫秒
1.
Campbell KL Borde-Perry WC Murtaugh KH Gidding SS Falkner B 《The American journal of the medical sciences》2002,323(5):231-237
BACKGROUND: Patients with type 2 diabetes have higher rates of cardiovascular events. Among African Americans, there is a higher prevalence of both cardiovascular disease and type 2 diabetes. Few studies have examined longitudinally the change in glucose tolerance in younger adult African Americans. METHODS: To examine the longitudinal relationship of glucose tolerance with other cardiovascular risk factors, 30 African American men and women aged 20 to 43 years were examined twice at an interval of 4 to 5 years. Cardiovascular risk factors, glucose tolerance, and insulin sensitivity (determined from euglycemic hyperinsulinemic clamp procedure) were assessed at each examination. Known diabetics were excluded from initial enrollment. The relationship of glucose tolerance status (normal, impaired, or diabetic glucose tolerance) to body mass index, blood pressure, cholesterol, and insulin sensitivity were further investigated. RESULTS: Initial oral glucose tolerance test identified 24 of 130 (18.5%) subjects with impaired glucose tolerance and 2 of 130 (1.5%) subjects with diabetes. Of the remaining 104 subjects with normal glucose tolerance, subsequent 5-year examination detected 31 (29.8%) with impaired glucose tolerance and 5 (4.8%) with diabetes. Those who later developed diabetes had higher mean systolic blood pressure (133 versus 121, P = 0.037) at exam 1. By exam 2, those with abnormal glucose tolerance had worse cardiovascular risk profiles and increased insulin resistance (P < 0.001). CONCLUSION: Conversion to abnormal glucose tolerance is relatively frequent in young adult African Americans. Deterioration in glucose tolerance may be preceded by higher systolic blood pressure and is accompanied by worsening of other cardiovascular risk factors and insulin resistance. 相似文献
2.
3.
Angeliki Bourazana Grigorios Giamouzis John Skoularigis Filippos Triposkiadis rew Xanthopoulos 《World journal of cardiology》2022,14(4):266-270
Diabetes mellitus (DM) is a health condition characterized by glucose dysregulation and affects millions of people worldwide. The presentation of heart failure in diabetic cardiomyopathy extends over a wide phenotypic spectrum, comm encing from asymptomatic, subclinical structural abnormalities to severely symptomatic biventricular dysfunction with increased mortality risk. Similarly, the spectrum of systolic dysfunction in diabetic-induced heart failure is diverse. DM leads also to cardiac electrical remodeling reacting on various targets. Dipeptidyl peptidase-4 (DPP-4) inhibitors reduce glucagon and blood glucose levels by raising levels of the endogenous hormones glucagon-like-peptide 1 and glucose-dependent insulinotropic peptide and constitute a safe and effective glucose lowering treatment option in patients with type 2 DM. Despite DPP-4 inhibitors’ efficacy regarding glycemic control, their effect on cardiovascular outcomes (myocardial infarction, stroke, hospitalization for heart failure, hospitalization for unstable angina, hospitalization for coronary revascularization, and cardiovascular death) in diabetic patients has been neutral. The potential correlation between atrial flutter and DPP-4 inhibitors administration needs further investigation. 相似文献
4.
BACKGROUND: The main aim of this study was to evaluate the additional utility of C-reactive protein (CRP) over traditional cardiovascular risk factors in risk prediction of cardiovascular outcomes. METHODS: In a nested case-control study, 207 cardiovascular events among participants over 30 years of the Tehran Lipid and Glucose Study (TLGS) were documented during 3 years of follow-up. Those cases that were free of cardiovascular disease at baseline (126 subjects) were matched to 259 controls for age and sex. High sensitivity CRP and traditional cardiovascular risk factors were measured at baseline. RESULTS: Modest correlation was found between CRP and body mass index (r=0.34), waist-to-hip ratio (r=0.22), total cholesterol (r=0.24) and calculated 10-year Framingham coronary risk score (FRS) (r=0.27) (all P values <0.001). The age and sex adjusted relative risk of cardiovascular events for subjects in the highest quartile of the population distribution of CRP compared with the lowest quartile was 2.6 (95% CI=1.4-5.1, P=0.006). After additional adjustment for traditional cardiovascular risk factors the odds ratio decreased to non-significant levels (0.8, 95% CI=0.3-1.9). Addition of CRP did not improve the area under receiver operating characteristic curve of risk functions that was based on traditional cardiovascular risk factors or FRS. CONCLUSION: It seems that for short-term prediction of cardiovascular disease outcomes in the Iranian population, measurement of CRP has no additional value when traditional cardiovascular risk factors are known. 相似文献
5.
6.
Glucose, insulin, and the cardiovascular system 总被引:8,自引:0,他引:8
7.
8.
Rosiglitazone and cardiovascular risk 总被引:1,自引:0,他引:1
A meta-analysis of 42 clinical trials suggested that rosiglitazone, a widely used thiazolidinedione, was associated with a
43% greater risk of myocardial infarction (P = 0.03) and a 64% greater risk of cardiovascular death (P = 0.06). However, a number of criticisms have been raised that potentially undermine the conclusions of this analysis. In
this article, we point out some of these limitations, summarize the currently available evidence concerning rosiglitazone
and cardiovascular risk, share implications for drug safety evaluation, and offer practical recommendations to health care
providers. We conclude that the data showing the increased risk for myocardial infarction and death from cardiovascular disease
for diabetic patients taking rosiglitazone are inconclusive. 相似文献
9.
10.
Aukrust P Halvorsen B Yndestad A Ueland T Øie E Otterdal K Gullestad L Damås JK 《Arteriosclerosis, thrombosis, and vascular biology》2008,28(11):1909-1919
Based on the importance of inflammation in atherogenesis, recent work has focused on whether plasma markers of inflammation can noninvasively diagnose and prognosticate atherosclerotic disorders. Although several studies support an important pathogenic role of chemokines in atherosclerosis, potentially representing attractive therapeutic targets in atherosclerotic disorders, this does not necessarily mean that chemokines are suitable parameters for risk prediction. In fact, the ability to reflect upstream inflammatory activity, stable levels in individuals, and high stability of the actual protein (eg, long half-life and negligible circadian variation) are additional important criteria for an ideal biomarker in cardiovascular disease. Although plasma/serum levels of certain chemokines (eg, interleukin- 8/CXCL8 and monocyte chemoattractant protein-1/CCL2) have shown to be predictive for future cardiac events in some studies, their role as clinical biomarkers is unclear, and their ability to predict subclinical atherosclerosis has been disappointing. Further prospective studies, including a larger number of patients, are needed to make any firm conclusion. Based on the participation of several chemokines in atherogenesis, it is possible that in the future, combined measurements of multiple chemokines could reveal as a "signature of disease" that can serve as a highly accurate method to assess for the presence of atherosclerotic disease. 相似文献
11.
Poorna R. Karuparthi Preethi Yerram Gurushankar Govindarajan Melvin R. Hayden 《Current cardiovascular risk reports》2008,2(2):113-119
Obesity has assumed epidemic proportions and is expected to decrease the life expectancy of current and future generations
by its cardiovascular complications and other associated chronic diseases. Recognizing the gravity of this trend, the American
Heart Association recently identified obesity as an independent and important modifiable risk factor for cardiovascular disease.
Obesity is known to cluster with other cardiovascular and metabolic risk factors constituting the cardiometabolic syndrome.
The pathophysiogic link between obesity and cardiovascular disease is complex and involves multiple metabolic and inflammatory
risk factors. In an attempt to better elucidate this major public health problem, this article reviews obesity as an epidemic,
the structural and functional changes in the cardiovascular system as a result of obesity, and the pathophysiology of obesity-related
cardiomyopathy. The sheer magnitude of the problem of obesity with its immense cardiovascular consequences warrants immediate
intervention. 相似文献
12.
13.
Through its classic effects on sodium and potassium homeostasis, aldosterone, when produced in excess, is associated with
the development of hypertension and hence with higher cardiovascular and renal risk. In recent years, experimental and epidemiologic
data have suggested that aldosterone also may be linked to high cardiovascular risk independently of its effects on blood
pressure. Thus, aldosterone has been associated with obesity and metabolic syndrome in selected populations, and these associations
may further contribute to the higher cardiovascular risk of subjects with elevated aldosterone levels. Moreover, aldosterone
has been reported to promote inflammation, oxidative stress, and fibrosis in a number of tissues. Clinical evidence indicates
that patients with primary hyperaldosteronism have a higher risk of developing cardiovascular and renal complications than
patients with essential hypertension who have the same level of blood pressure. Aldosterone receptor blockade has been shown
to lower cardiovascular mortality after myocardial infarction and in patients with congestive heart failure. Some studies
have also demonstrated that aldosterone blockade could have a favorable impact on the progression of renal disease. However,
prospective interventional trials are needed to further evaluate the impact of blockade of aldosterone on cardiovascular risk. 相似文献
14.
15.
16.
Cardiovascular diseases represent, today, the principal cause of mortality in the general population, especially in subjects with type 2 diabetes mellitus. In these patients the risk of death from cardiovascular diseases is equal to that of non-diabetic subjects with a previous episode of myocardial infarction. Many factors concur to determine such high risk. Hyperglycaemia contributes to the increase in morbidity and cardiovascular mortality associated with diabetes mellitus. Hyperglycaemia acts as a multiplier of cardiovascular risk due to frequent association of multiple risk factors in diabetic patients. Therefore, effective treatment requires a more complete assessment of quantitative and qualitative aspects of glycemic control as well as all components of the diabetic syndrome or, more commonly, metabolic syndrome. 相似文献
17.
Giacomo Tirabassi Angelo Gioia Lara Giovannini Marco Boscaro Giovanni Corona Angelo Carpi Mario Maggi Giancarlo Balercia 《Internal and emergency medicine》2013,8(1):65-67
Cardiovascular (CV) disease is one of the most common causes of death in the western populations and, nowadays, its incidence is increasing even in the developing countries; although CV disease affects both sexes, it is more frequent in males in whom it shortens the average life expectancy. In this regard, this difference has been wrongly attributed for many years to the negative effects of testosterone (T); however, nowadays, a large amount of evidence suggests that this hormone may have protective effects on the CV system and that, indeed, the low levels of T could be associated with an increased CV risk and with an augmentation of morbidity and mortality in males. Such an aspect gains great relevance in light of the consideration that T decrease, besides occurring as a consequence of rare pathological conditions, can often take place with natural aging, causing a state of “male menopause”, also called late-onset hypogonadism. In this review, we aimed to summarize the present state of the art concerning the association between T deficit and CV disease by analyzing the protective role of T on CV system and the relationship of this hormonal lack with metabolic syndrome, CV morbidity and mortality, and with the CV complications, such as ischemic heart disease, heart failure and stroke, that frequently occur in T deficiency. 相似文献
18.
19.
Microalbuminuria and cardiovascular risk 总被引:3,自引:0,他引:3
Microalbuminuria is a marker for generalized vascular dysfunction. Its prevalence in United States and European general population surveys ranges from 6% to 10%. Increased risk for cardiovascular morbidity and mortality begins with albumin excretion rates that are well within normal limits. Although microalbuminuria interacts with the traditional cardiovascular risk factors, it has an independent relationship to renal and cardiovascular outcomes. For example, microalbuminuria doubles the risk for a cardiovascular event in patients with type 2 diabetes mellitus even after adjusting for the usual risk factors. Elevated rates of urinary albumin excretion predict target organ damage, notably renal disease, but are also related to left ventricular dysfunction, stroke, and myocardial infarction. Screening for microalbuminuria, which is recommended by several expert committees and associations, has become a readily accessible procedure. Screening can give clinicians prognostic information concerning cardiovascular risk and assist in guiding therapy. The goal of treatment is to prevent progression of, and even to reverse, microalbuminuria. Abundant evidence demonstrates that antihypertensive therapy is an important key to the control of urinary albumin excretion, and blockade of the renin-angiotensin system (with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers) is the treatment of choice. These drugs have successfully halted or delayed the progression to nephropathy and have reversed elevated rates of albumin excretion to normal values, even when blood pressure reduction has been minimal. 相似文献
20.